Frequency and Severity of Allergic Reactions to Non-Mandatory Labelled Allergenic Foods-Data From Two Large European Cohorts

Allergic Diseases

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

Allergy

Boyd H, Bartha I, Foong RX, Krawiec M, Marques-Mejias A, Marshall HF, Radulovic S, Harrison F, Antoneria G, Jama Z, Kwok M, Pietraszewicz E, Eghleilib M, Ricci C, Marrs T, Lack G, Du Toit G, Santos AF

doi: 10.1111/all.70175

Allergic Diseases

Diverse Food Allergen IgG Reactivities Are Associated With Food Allergies in the Boston Birth Cohort

Allergy

Angkeow JW, Hong X, Thakar M, Frischmeyer-Guerrerio PA, Wang X, Larman HB

doi: 10.1111/all.70246

Allergic Diseases

Transcriptomic Analysis of Allergic Patch Test Reactions in Non-Atopic Patients: A Comparative Study Across Multiple Allergens

Allergy

Pesqué D, Andrades E, Berenguer-Molins P, Perera-Bel J, Clarós M, Bódalo-Torruella M, González-Farré M, Gallardo F, Pujol RM, Giménez-Arnau AM

doi: 10.1111/all.16642

Allergic Diseases

Omalizumab Dose-Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study

Allergy

Arasi S, Bitetti C, Lo Scalzo L, Spagnoli A, Fabrizi E, Fiocchi A, Cafarotti A

doi: 10.1111/all.70228

Gout

Long-term lignan intake, whole grain foods, and the risk of gout: results from two prospective cohort studies

Arthritis Care Res (Hoboken)

Rai SK, Hu Y, Ding M, Hu FB, Wang M, Chavarro JE, McCormick N, Choi HK, Sun Q

doi: 10.1002/acr.25596

Rheumatoid Arthritis

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomised, controlled, open-label, non-inferiority trial

Rheumatology (Oxford)

Blanco FJ, Galindo L, Acasuso B, Balboa-Barreiro V, Cañete JD, Fernández-Gutiérrez B, González-Álvaro I, Álvarez JLP, Bejerano-Herrería C, Silva-Díaz M, Rego-Perez I, Lourido L, Ruiz-Romero C, Uriarte-Ecenarro M, García-Vicuña R, Cuervo A, Ramírez J, Celis R, Rodríguez-Rodríguez L, Abasolo Alcázar L, Nuñez DF, Martín-López M, Toro-Santos FJ, Oreiro N

doi: 10.1093/rheumatology/keag050

Further Publications Rheumatology

Almost half of the patients with axial spondyloarthritis reporting an acceptable symptom state have high disease activity; data from two standard-of-care cohorts

Semin Arthritis Rheum

Carbo M, Kampman A, Paap D, Wink F, Webers C, Vonkeman H, van Tubergen A, Arends S, Spoorenberg A

doi: 10.1016/j.semarthrit.2025.152903

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Autoimmune Disease

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up

Semin Arthritis Rheum

Signorelli F, Balbi GGM, Bastos VP, Reis-Carvalho T, Klumb EM, Levy RA

doi: 10.1016/j.semarthrit.2025.152873

Related content

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

Diverse Food Allergen IgG Reactivities Are Associated With Food Allergies in the Boston Birth Cohort

Transcriptomic Analysis of Allergic Patch Test Reactions in Non-Atopic Patients: A Comparative Study Across Multiple Allergens

Omalizumab Dose-Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study

Long-term lignan intake, whole grain foods, and the risk of gout: results from two prospective cohort studies

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomised, controlled, open-label, non-inferiority trial

Almost half of the patients with axial spondyloarthritis reporting an acceptable symptom state have high disease activity; data from two standard-of-care cohorts

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up